The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 4, 2007, Pages 401-410

  Klein, Cheri Enders ^a   Chiu, Yi Lin ^a   Awni, Walid ^a   Zhu, Tong ^a   Heuser, Renee S ^a   Doan, Thao ^a   Breitenbach, Joerg ^b   Morris, John B ^a   Brun, Scott C ^a   Hanna, George J ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Bioavailability; Food effect; Lopinavir; Melt extrusion; Pharmacokinetics; Ritonavir

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; FEMALE; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; GELATIN; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; TABLETS;

EID: 34147176581     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31803133c5     Document Type: Article

References (11)

1. Abbott Laboratories. Kaletra, US package insert. Available at: http://www.fda.gov/cder/foi/label/2005/021226s016lbl.pdf. Accessed October 25, 2006.
2. Gustavson L, Lam W, Bertz R, et al. Assessment of the bioequivalence and food effects for liquid and soft gelatin capsule co-formulations of ABT-378/ritonavir (ABT-378/r) in healthy subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto.
3. Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J Pharm Sci. 2004;93:563-570.
4. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47-60.
5. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm. 2002;54:107-117.
6. Breitenbach J, Maegerlein M. Melt extruded molecular dispersions. In: Martin C, ed. Drugs and the Pharmaceutical Sciences, vol. 133. New York: Marcel Dekker; 2003.
7. Breitenbach J. Melt extrusion can bring new benefits to HIV therapy: the example of Kaletra tablets. American Journal of Drug Delivery. 2006;4:61-64.
8. Schuirman DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-680.
9. SAS Institute. The MIXED procedure. In: SAS/STAT Software Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute; 1996.
10. US Food and Drug Administration. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. FDA biopharmaceutics guidance. Available at: http://www.fda.gov/cder/guidance/ 5356fnl.pdf. Accessed October 25, 2006.
11. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.